

Susumu Kusunoki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3154233/publications.pdf>

Version: 2024-02-01

122
papers

4,727
citations

136950

32
h-index

110387

64
g-index

130
all docs

130
docs citations

130
times ranked

3091
citing authors

#	ARTICLE	IF	CITATIONS
1	Hemiplegic migraine type 2 with new mutation of the ATP1A2 gene in Japanese cases. <i>Neuroscience Research</i> , 2022, , .	1.9	2
2	Predicting Outcome in Guillain-Barré Syndrome. <i>Neurology</i> , 2022, 98, .	1.1	22
3	Finger drop sign as a new variant of acute motor axonal neuropathy. <i>Muscle and Nerve</i> , 2021, 63, 336-343.	2.2	4
4	A Guillain-Barré syndrome-associated SIGLEC10 rare variant impairs its recognition of gangliosides. <i>Journal of Autoimmunity</i> , 2021, 116, 102571.	6.5	10
5	Chondroitin sulfate <i>N</i> -acetylgalactosyltransferase-1 knockout shows milder phenotype in experimental autoimmune encephalomyelitis than in wild type. <i>Glycobiology</i> , 2021, 31, 260-265.	2.5	4
6	Electroencephalographic findings in Bickerstaff's brainstem encephalitis: A possible reflection of the dysfunction of the ascending reticular activating system. <i>Clinical Neurophysiology Practice</i> , 2021, 6, 29-35.	1.4	5
7	HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data. <i>Scientific Reports</i> , 2021, 11, 607.	3.3	19
8	Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1080-1088.	1.9	6
9	Unclassified subtype of Guillain-Barré syndrome is associated with quick recovery. <i>Journal of Clinical Neuroscience</i> , 2021, 91, 313-318.	1.5	1
10	COQ2 V393A confers high risk susceptibility for multiple system atrophy in East Asian population. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117623.	0.6	17
11	Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 311-318.	1.9	21
12	CSF sphingomyelin: possible biomarker of demyelination. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 232-232.	1.9	1
13	New-onset Refractory Status Epilepticus Involving the Limbic System, Spinal Cord, and Peripheral Nerves. <i>Internal Medicine</i> , 2020, 59, 267-270.	0.7	4
14	Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 113-121.	1.9	34
15	Childhood-onset multifocal motor neuropathy with IgM antibodies to GM2 and GalNac-GD1a. <i>Brain and Development</i> , 2020, 42, 88-92.	1.1	3
16	Unique HLA haplotype associations in IgG4 anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy. <i>Journal of Neuroimmunology</i> , 2020, 339, 577139.	2.3	18
17	Charcot-Marie-Tooth disease with a mutation in FBLN5 accompanying with the small vasculitis and widespread onion-bulb formations. <i>Journal of the Neurological Sciences</i> , 2020, 410, 116623.	0.6	5
18	Association of variability in antibody binding affinity with a clinical course of anti-MAG neuropathy. <i>Journal of Neuroimmunology</i> , 2020, 339, 577127.	2.3	2

#	ARTICLE	IF	CITATIONS
19	Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1339-1342.	1.9	13
20	Bickerstaff brainstem encephalitis with or without anti-GQ1b antibody. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	21
21	Neutral Lipid Storage Disease Associated with the <i>PNPLA2</i> Gene: Case Report and Literature Review. <i>European Neurology</i> , 2020, 83, 317-322.	1.4	4
22	Bardet-Biedl syndrome and related disorders in Japan. <i>Journal of Human Genetics</i> , 2020, 65, 847-853.	2.3	9
23	PSP-Phenotype in SCA8: Case Report and Systemic Review. <i>Cerebellum</i> , 2019, 18, 76-84.	2.5	11
24	Intrathecal cytokine profile in neuropathy with anti-neurofascin 155 antibody. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2304-2316.	3.7	11
25	Current treatment practice of Guillain-Barré syndrome. <i>Neurology</i> , 2019, 93, e59-e76.	1.1	57
26	Guillain-Barré syndrome and related diseases after influenza virus infection. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e575.	6.0	20
27	The novel de novo mutation of KIF1A gene as the cause for Spastic paraplegia 30 in a Japanese case. <i>ENeurologicalSci</i> , 2019, 14, 34-37.	1.3	18
28	A case report of Fisher syndrome with the detection of anti-GM3 and anti-GD1b IgG antibodies. <i>Neurological Sciences</i> , 2019, 40, 891-893.	1.9	1
29	6. Pathogenesis and Treatments of Autoimmune Neuropathies. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2019, 108, 481-486.	0.0	0
30	Mechanism and spectrum of anti-glycolipid antibody-mediated chronic inflammatory demyelinating polyneuropathy. <i>Clinical and Experimental Neuroimmunology</i> , 2018, 9, 65-74.	1.0	1
31	Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. <i>Lancet Neurology</i> , The, 2018, 17, 519-529.	10.2	111
32	Clinical Features of Acute Flaccid Myelitis Temporally Associated With an Enterovirus D68 Outbreak: Results of a Nationwide Survey of Acute Flaccid Paralysis in Japan, August-December 2015. <i>Clinical Infectious Diseases</i> , 2018, 66, 653-664.	5.8	110
33	Nationwide epidemiological study of neuromyelitis optica in Japan. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 667-668.	1.9	42
34	Diagnosis of Parkinson's disease and the level of oxidized DJ-1 protein. <i>Neuroscience Research</i> , 2018, 128, 58-62.	1.9	15
35	Electron microscopic abnormality and therapeutic efficacy in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin155 immunoglobulin G4 antibody. <i>Muscle and Nerve</i> , 2018, 57, 498-502.	2.2	26
36	Regional variation of Guillain-Barré syndrome. <i>Brain</i> , 2018, 141, 2866-2877.	7.6	190

#	ARTICLE	IF	CITATIONS
37	Varied antibody reactivities and clinical relevance in anti-GQ1b antibody-related diseases. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e501.	6.0	26
38	Noncoding repeat expansions for ALS in Japan are associated with the <i>ATXN8OS</i> gene. <i>Neurology: Genetics</i> , 2018, 4, e252.	1.9	19
39	International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 68-76.	3.1	89
40	Characterization of the neurological diseases associated with <i>Mycoplasma pneumoniae</i> infection and anti-glycolipid antibodies. <i>Journal of Neurology</i> , 2017, 264, 467-475.	3.6	29
41	Markers for Guillain-Barré syndrome with poor prognosis: a multicenter study. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 433-439.	3.1	46
42	Modified method of intravenous immunoglobulin administration for patients with intractable multifocal motor neuropathy: A case report. <i>Clinical and Experimental Neuroimmunology</i> , 2017, 8, 141-145.	1.0	0
43	Miller Fisher syndrome with sinus arrest. <i>Neurology International</i> , 2017, 9, 7312.	2.8	3
44	Ganglionic acetylcholine receptor autoantibodies in patients with Guillain-Barré syndrome. <i>Journal of Neuroimmunology</i> , 2016, 295-296, 54-59.	2.3	10
45	Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2016, 15, 1129-1137.	10.2	66
46	Electrophysiological assessment of Guillain-Barré syndrome with both Gal-C and ganglioside antibodies; tendency for demyelinating type. <i>Journal of Neuroimmunology</i> , 2016, 301, 61-64.	2.3	7
47	History of Guillain-Barré syndrome. <i>Clinical and Experimental Neuroimmunology</i> , 2016, 7, 305-311.	1.0	4
48	Serological study using glycoarray for detecting antibodies to glycolipids and glycolipid complexes in immune-mediated neuropathies. <i>Journal of Neuroimmunology</i> , 2016, 301, 35-40.	2.3	20
49	Chondroitin sulfate β -1,4-N-acetylgalactosaminyltransferase-1 (ChGn-1) polymorphism: Association with progression of multiple sclerosis. <i>Neuroscience Research</i> , 2016, 108, 55-59.	1.9	11
50	Recurrent Guillain-Barré syndrome, Miller Fisher syndrome and Bickerstaff brainstem encephalitis. <i>Journal of the Neurological Sciences</i> , 2016, 364, 59-64.	0.6	31
51	A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS). <i>JMIR Research Protocols</i> , 2016, 5, e210.	1.0	18
52	Guillain-Barré Syndrome: Epidemiology, Diagnosis, and Treatment. , 2016, , 153-164.		0
53	Neuropathogenesis of Zika Virus Infection : Potential Roles of Antibody-Mediated Pathology. <i>Acta Medica Kinki University</i> , 2016, 41, 37-52.	3.0	9
54	Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 960-971.	3.7	148

#	ARTICLE	IF	CITATIONS
55	A multicentre prospective study of Guillain-Barré Syndrome in Japan: a focus on the incidence of subtypes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 110-114.	1.9	49
56	Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial. <i>BMJ Open</i> , 2015, 5, e007330-e007330.	1.9	14
57	The first Japanese familial case of spinocerebellar ataxia 23 with a novel mutation in the PDYN gene. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 332-334.	2.2	8
58	Binding specificity of anti-HNK-1 IgM M-protein in anti-MAG neuropathy: Possible clinical relevance. <i>Neuroscience Research</i> , 2015, 91, 63-68.	1.9	14
59	Prevalence of Anti-Ganglioside Antibodies and Their Clinical Correlates with Guillain-Barré Syndrome		

#	ARTICLE	IF	CITATIONS
73	Nationwide survey of patients in Japan with Bickerstaff brainstem encephalitis: epidemiological and clinical characteristics. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1210-1215.	1.9	74
74	Refractory acute disseminated encephalomyelitis with anti-galactocerebroside antibody. <i>Neuroscience Research</i> , 2012, 74, 284-289.	1.9	16
75	Neuropathophysiological potential of Guillain-Barré syndrome anti-ganglioside-complex antibodies at mouse motor nerve terminals. <i>Clinical and Experimental Neuroimmunology</i> , 2011, 2, 59-67.	1.0	11
76	Antibodies against ganglioside complexes in Guillain-Barré syndrome and related disorders. <i>Journal of Neurochemistry</i> , 2011, 116, 828-832.	3.9	74
77	Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. <i>Journal of Neuroimmunology</i> , 2011, 239, 87-90.	2.3	53
78	Chondroitin beta-1,4-N-acetylgalactosaminyltransferase-1 missense mutations are associated with neuropathies. <i>Journal of Human Genetics</i> , 2011, 56, 143-146.	2.3	27
79	Antibodies to gangliosides and ganglioside complexes in Guillain-Barré syndrome and Fisher syndrome: Mini-review. <i>Journal of Neuroimmunology</i> , 2010, 223, 5-12.	2.3	84
80	Antibodies to ganglioside complexes consisting of asialo-GM1 and GQ1b or GT1a in Fisher and Guillain-Barré syndromes. <i>Journal of Neuroimmunology</i> , 2009, 214, 125-127.	2.3	22
81	Guillain-Barré syndrome: update on immunobiology and treatment. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1307-1319.	2.8	21
82	Characterization of a phospholipid antigen reacting with serum antibody in patients with peripheral neuropathies and paraproteinemia. <i>Journal of Neurochemistry</i> , 2008, 79, 970-975.	3.9	5
83	Apoptosis of primary sensory neurons in GD1b-induced sensory ataxic neuropathy. <i>Experimental Neurology</i> , 2008, 209, 279-283.	4.1	29
84	Antibodies against gangliosides and ganglioside complexes in Guillain-Barré syndrome: New aspects of research. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2008, 1780, 441-444.	2.4	55
85	Ganglioside complexes as target antigens in Guillain-Barré syndrome and related disorders. <i>Future Lipidology</i> , 2008, 3, 425-434.	0.5	3
86	Predictors of respiratory failure in Guillain-Barré syndrome. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 430-431.	2.5	0
87	Letter to the Editor. <i>Muscle and Nerve</i> , 2006, 33, 828-829.	2.2	5
88	Guillain-Barre syndrome with antibodies to GD1a/GD1b complex. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 548-549.	1.9	4
89	Harmful effects of anti-GalNAc-GD1a antibodies and TNF-alpha on rat dorsal root ganglia. <i>Journal of the Peripheral Nervous System</i> , 2005, 10, 190-201.	3.1	9
90	Effects of phospholipids on antiganglioside antibody reactivity in GBS. <i>Journal of Neuroimmunology</i> , 2005, 159, 129-132.	2.3	19

#	ARTICLE	IF	CITATIONS
91	Ganglioside complexes as new target antigens in Guillain-Barré syndrome. <i>Annals of Neurology</i> , 2004, 56, 567-571.	5.3	156
92	Binding of immunoglobulin G antibodies in Guillain-Barré syndrome sera to a mixture of GM1 and a phospholipid: Possible clinical implications. <i>Muscle and Nerve</i> , 2003, 27, 302-306.	2.2	25
93	Diagnosis, pathogenesis and treatment of Miller Fisher syndrome and related disorders: clinical significance of antiGQ1b IgG antibody. <i>Expert Review of Neurotherapeutics</i> , 2003, 3, 133-140.	2.8	6
94	Expression of the β -Galactoside \pm 1,2-Fucosyltransferase Gene Suppresses Axonal Outgrowth of Neuro2a Neuroblastoma Cells. <i>Journal of Neurochemistry</i> , 2002, 66, 1633-1640.	3.9	12
95	Dorsal Root Ganglia-Specific Expression of the β -Galactoside \pm 1,2-Fucosyltransferase Genes in Rabbits. <i>Journal of Neurochemistry</i> , 2002, 70, 2174-2178.	3.9	7
96	Variability in immunohistochemistries of IgM M-proteins binding to sulfated glucuronyl paragloboside. <i>Journal of Neuroimmunology</i> , 2001, 116, 206-212.	2.3	6
97	Chronic motor axonal neuropathy associated with antibodies monospecific for n-acetylgalactosaminyl GD1a. <i>Muscle and Nerve</i> , 2000, 23, 702-706.	2.2	32
98	Elevation in anti-GQ1b, anti-GT1a, and anti-GT1b IgG antibodies in postinfectious acute ataxic neuropathy with oropharyngeal palsy but without ophthalmoplegia. <i>Journal of Neurology</i> , 2000, 247, 566-567.	3.6	11
99	Antiglycolipid Antibodies in Guillain-Barré Syndrome and Autoimmune Neuropathies. <i>American Journal of the Medical Sciences</i> , 2000, 319, 234-239.	1.1	33
100	Monospecific anti-GD1b IgG is required to induce rabbit ataxic neuropathy. <i>Annals of Neurology</i> , 1999, 45, 400-403.	5.3	60
101	An unusual case of facial diplegia. , 1999, 22, 778-779.		6
102	Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia. , 1999, 22, 1071-1074.		126
103	Clinicopathological study of an autopsy case with sensory-dominant polyradiculoneuropathy with antiganglioside antibodies. <i>Muscle and Nerve</i> , 1999, 22, 1426-1431.	2.2	20
104	Sensorimotor polyneuropathy associated with chronic lymphocytic leukemia, IgM antigangliosides antibody and human T-cell leukemia virus I infection. <i>Muscle and Nerve</i> , 1999, 22, 1461-1465.	2.2	23
105	Rabbit experimental sensory ataxic neuropathy: anti-GD1b antibody-mediated trkC downregulation of dorsal root ganglia neurons. <i>Neuroscience Letters</i> , 1999, 260, 157-160.	2.1	19
106	Degeneration of rabbit sensory neurons induced by passive transfer of anti-GD1b antiserum. <i>Neuroscience Letters</i> , 1999, 273, 33-36.	2.1	26
107	Serum antibody against a peripheral nerve myelin ganglioside, LM1, in Guillain-Barré syndrome. <i>Journal of the Neurological Sciences</i> , 1999, 168, 85-89.	0.6	42
108	Acute isolated ophthalmoplegia as a variant of Miller-Fisher syndrome. , 1998, 21, 1107-1107.		10

#	ARTICLE	IF	CITATIONS
109	Severe motor-dominant neuropathy with IgM M-protein binding to the NeuAc \pm 2-3Gal β 2 moiety. Journal of the Neurological Sciences, 1998, 154, 4-7.	0.6	18
110	Antiganglioside Antibodies in Guillain-Barré Syndrome. Internal Medicine, 1997, 36, 599-600.	0.7	1
111	Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Research, 1997, 745, 32-36.	2.2	261
112	Binding of antibodies against GM1 and GD1b in human peripheral nerve. , 1997, 20, 840-845.		51
113	A novel ganglioside, 9-O-acetyl GD1b, is recognized by serum antibodies in Guillain-Barré syndrome. Journal of Neuroimmunology, 1996, 66, 95-101.	2.3	20
114	Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Annals of Neurology, 1996, 39, 424-431.	5.3	182
115	IgM M-protein with antibody activity against gangliosides with disialosyl residue in sensory neuropathy binds to sensory neurons. , 1996, 19, 528-530.		26
116	Letters to the editor. Muscle and Nerve, 1996, 19, 254-260.	2.2	0
117	Anti-gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection. Muscle and Nerve, 1995, 18, 409-413.	2.2	89
118	N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome. Annals of Neurology, 1994, 35, 570-576.	5.3	172
119	Cerebellar ataxia and polyneuropathy in a patient with IgM M-protein specific to the Gal(β 1-3) GalNAc epitope. Journal of the Neurological Sciences, 1994, 126, 219-224.	0.6	20
120	Acute conduction block in vitro following exposure to antiganglioside sera. Muscle and Nerve, 1993, 16, 587-593.	2.2	113
121	Localization of GM1 and GD1b antigens in the human peripheral nervous system. Muscle and Nerve, 1993, 16, 752-756.	2.2	105
122	Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Annals of Neurology, 1992, 31, 677-679.	5.3	528